The Application dimension of the High Purity Process Systems for Biopharmaceuticals market is driven primarily by four product categories: Therapeutic proteins, Vaccines, Cell therapy and Gene therapy. Therapeutic proteins dominate the landscape, accounting for roughly 45 % of total spend, reflecting their entrenched commercial pipelines and the high‑volume manufacturing requirements that demand robust, continuous purification platforms. Vaccines represent about 25 % of the market, a share that has expanded with the rise of mRNA and recombinant technologies, which require flexible, rapid‑turnaround systems to meet fluctuating demand. Cell‑based therapies, contributing 20 %, rely on single‑use, closed‑system designs to preserve sterility and reduce cross‑contamination risk during complex, small‑batch productions. Gene therapy, while still nascent, commands a 10 % slice, as its vector purification processes increasingly adopt high‑purity chromatography and viral clearance modules. Together, these applications shape the overall market size, and their relative weight is captured in the High Purity Process Systems for Biopharmaceuticals segmentation chart.